Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
CON vs. MEDP: Which Stock Is the Better Value Option?
Zacks
More News
Can AI Innovation and CRM Wins Boost Veeva Systems' Q2 Results?
VEEV heads into Q2 with Falcon AI, Vault CRM wins and R&D Cloud growth in focus as revenue and EPS estimates point to double-digit gains.
Zacks
Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?
Medpace (MEDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Zacks
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Zacks
If You Invested $100 In Medpace Holdings Stock 5 Years Ago, You Would Have This Much Today
Medpace Holdings (NASDAQ:MEDP) has outperformed the market over the past 5 years by 14.56% on an annualized basis producing an average annual return of 26.38%. Currently, Medpace Holdings has a market capitalization ofread more...
Benzinga
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.
Zacks
Insider Decision: August J Troendle Offloads $13.98M Worth Of Medpace Holdings Stock
A substantial insider sell was reported on August 12, by August J Troendle, President & CEO at Medpace Holdings (NASDAQ:MEDP), based on the recent SEC filing. What Happened: Troendle's recent Form 4 filing withread more...
Benzinga
National Vision Stock Down Despite Q2 Earnings & Revenue Beat
EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.
Zacks
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
Zacks

Advertisement|Remove ads.